This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Nonetheless, ECB Vice President Luis de Guindos stated that central bank liquidity swap lines between the Federal Reserve and the ECB remained "business as usual". International Monetary Fund Director Kristalina Georgieva also spoke in defense of Powell and the Federal Reserve's independence given the role of the United States dollar as the world's reserve currency.
== Funding and infrastructure == Initial construction costs were covered by the ERDF and Czech state funds. Operational funding comes from competitive grants, including Czech Science Foundation (GACR) awards and Horizon Europe projects. The campus features a cogeneration plant and rainwater recycling systems.
==== Mechanism of action ==== One of the components in nabiximol, tetrahydrocannabinol (THC), weakly stimulates cannabinoid receptor 1(CBR1) and cannabinoid receptor 2 (CBR2) to produce analgesic effect (pain relief). Another component of nabiximol, cannabidiol (CBD), slightly inhibits the proliferation of T cells (a type of immune cells) and the activity of microglia (cells within the brain that regulate neural activity and repair).
=== October === 1 October – John Braggins, botanist and bryologist (University of Auckland, Auckland War Memorial Museum) (born 1944). 2 October – Mac Gardner, clinical geneticist (University of Otago, University of Melbourne) (born 1942). 4 October – Gordon Keys, atmospheric scientist (DSIR, NIWA), Royal Society of New Zealand Science and Technology Silver Medal (1995) (born 1930). 6 October – Margaret, Lady Liley, paediatrician, general practitioner and farmer (born 1928). 7 October – Graham Bell, police officer and television presenter (Police Ten 7) (born 1946). 8 October – Wally Yovich, businessman, local politician and philanthropist, Whangārei District Councillor (1989–1995) (born 1939). 9 October – Cliff Tait, aviator, politician and writer, Hamilton City Councillor (1992–1995) (born 1929). 10 October – Roger Harris, cricketer (Auckland, national team) (born 1933). 11 October – Richard Nottage, diplomat and public servant, ambassador to Indonesia (1980–1982) and Japan (1987–1988), permanent representative to the UN in Geneva (1984–1987), Secretary of Foreign Affairs and Trade (1991–1999) (born 1939). 15 October – Jim Bolger, politician, MP for King Country (1975–1996) and Taranaki-King Country (1996–1998), Minister of Labour (1978–1984), leader of the National Party (1986–1997), Prime Minister (1990–1997), Ambassador to the United States (1998–2002), chancellor of the University of Waikato (2007–2019), Privy Counsellor (since 1991), Member of the Order of New Zealand (since 1997) (born 1935). 20 October – So You Think, Hall of Fame Thoroughbred racehorse, W. S.
Sources: en.wikipedia.org
=== Radiation protection associations === The Association of German Radiation Protection Physicians (VDSÄ) was formed in the late 1950s from a working group of radiation protection physicians of the German Red Cross and was founded in 1964. It was dedicated to the promotion of radiation protection and the representation of medical, dental, and veterinary radiation protection concerns to the public and the health care system. In 2017, it was merged into the Professional Association for Radiation Protection. The Austrian Association for Radiation Protection (ÖVS), founded in 1966, pursues the same goals as the Association for Medical Radiation Protection in Austria. The Professional Association for Radiation Protection for Germany and Switzerland is networked worldwide.
SEA is an abbreviation of bis(2-sulfanylethyl)amido (Scheme 1). SEA ligation involves the reaction of a peptide featuring a C-terminal bis(2-sulfanylethyl)amido group with a Cys peptide. This reaction proceeds probably through the formation of a transient thioester intermediate, obtained by intramolecular attack of one SEA thiol on the peptide C-terminal carbonyl group as shown in Scheme 1. Then, the thioester undergoes a series of thiol-thioester exchanges, including with exogeneous thiols present in the ligation mixture such as mercaptophenyl acetic acid (MPAA). Exchange with the cysteine thiol group of the second peptide segment results in a transient thioester intermediate, which as for Native Chemical Ligation, rearranges by intramolecular S,N-acyl shift migration into a native peptide bond.
Pindolol is a first generation, non-selective beta blocker in the class of β-adrenergic receptor antagonists. On the receptor level it is a competitive partial agonist. It possesses intrinsic sympathomimetic activity, meaning it has some degree of agonist effects in the absence of competing ligands. Pindolol shows membrane-stabilizing effects like quinidine, possibly accounting for its antiarrhythmic effects. It also acts as a serotonin 5-HT1A receptor partial agonist (intrinsic activity = 20–25%) or functional antagonist. The drug additionally shows affinity for the serotonin 5-HT1B receptor.
Sources: en.wikipedia.org
Ultraviolet radiation (UV; sometimes called ultraviolet light) is electromagnetic radiation of wavelengths of 100–400 nanometers, shorter than that of visible light, but longer than vacuum ultraviolet and extreme ultraviolet, radiation bands that overlaps UV but shares some properties with soft X-rays. UV radiation is present in sunlight and constitutes about 10% of the total electromagnetic radiation output from the Sun. It is also produced by electric arcs, Cherenkov radiation, and specialized lights, such as mercury-vapor lamps, tanning lamps, and black lights. The photons of ultraviolet have greater energy than those of visible light, from about 3.1 to 12 electron volts, around the minimum energy required to ionize atoms. Although long-wavelength ultraviolet is not considered an ionizing radiation because its photons lack sufficient energy, it can induce chemical reactions and cause many substances to glow or fluoresce. Many practical applications, including chemical and biological effects, are derived from the way that UV radiation can interact with organic molecules. These interactions can involve exciting orbital electrons to higher energy states in molecules potentially breaking chemical bonds. In contrast, the main effect of longer wavelength radiation is to excite vibrational or rotational states of these molecules, increasing their temperature. UV damages DNA and sterilizes surfaces with which it comes into contact. For humans, suntan and sunburn are familiar effects of exposure of the skin to UV, along with an increased risk of skin cancer.
The British and Colonial Aeroplane Company, which later became the Bristol Aeroplane Company, then part of the British Aircraft Corporation and finally BAE Systems, was founded by Sir George White, owner of Bristol Tramways in 1910. During World War I production of the Bristol Scout and the Bristol F.2 Fighter established the reputation of the company. The main base at Filton is still a prominent manufacturing site for BAE Systems in the 21st century. The Bristol Aeroplane Company's engine department became a subsidiary company Bristol Aero Engines, then Bristol Siddeley Engines; and were bought by Rolls-Royce Limited in 1966, to become Rolls-Royce plc which is still based at Filton. Shipbuilding in the city docks, predominately by Charles Hill & Sons, formerly Hilhouse, remained important until the 1970s. Other prominent industries included chocolate manufacturers J. S. Fry & Sons and wine and sherry importers John Harvey & Sons. Bristol City F.C. (formed in 1897) joined the Football League in 1901 and became runners up in the First Division in 1906 and losing FA Cup finalists in 1909. Rivals Bristol Rovers F.C. (formed in 1883) joined the league in 1920. Gloucestershire County Cricket Club was formed in 1870 and have been runners up in the County Championship many times since. Bristol City Council built over 15,000 houses between 1919 and 1939, enabling clearance of some of the worst slums in the city centre. The new estates were at Southmead, Knowle, Filwood Park, Sea Mills and Horfield. The city boundaries were extended to north and south to accommodate this growth.
=== Insect-resistant crops === Bacillus thuringiensis is a bacterium that naturally produces a protein (Bt toxin) with insecticidal properties. The bacterium has been applied to crops as an insect-control strategy for many years, and this practice has been widely adopted in agriculture and gardening. Recently, plants have been developed that express a recombinant form of the bacterial protein, which may effectively control some insect predators. Environmental issues associated with the use of these transgenic crops have not been fully resolved.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.